Drug Formulary Review articles from December 2005

Drug Formulary Review archives from December 2005

Drug-induced diseases have become an increasing problem.
December 1, 2005... Drug-induced diseases have become an increasing problem Pharmacists create a resource, suggest process for determining AEs Much has been written about drugs and their adverse effects (AEs). But two pharmacists saw the need for a central...

Enrollment begins for Medicare Part D.
December 1, 2005... Enrollment begins for Medicare Part D Seniors looking to physicians, pharmacists for info Seniors finally had the opportunity to enroll in a Medicare Part D plan beginning Nov. 15. More than half of those eligible, however, still are...

FDA predicts more vaccine production than last year.
December 1, 2005... FDA predicts more vaccine production than last year Shipments suspended after reports of hoarding Don't expect a repeat of last year's shortage of influenza vaccine this winter. Do expect, however, to hear more about preparing for a...

Research News: Trastuzumab trial results 'stunning' in early-stage HER2-positive breast cancer.
December 1, 2005... Trastuzumab trial results 'stunning' in early-stage HER2-positive breast cancer Results from recent published trials have shown much promise in the use of trastuzumab (Herceptin) plus adjuvant chemotherapy in patients with HER2-positive...

News Briefs.
December 1, 2005... FDA: Manufacturers must use electronic drug labels The FDA has begun requiring drug manufacturers to submit prescription drug label information to the agency in a new electronic format. This electronic format will allow health care...

Drug Criteria & Outcomes: Entecavir (Baraclude) Formulary Evaluation.
December 1, 2005... Drug Criteria & Outcomes Entecavir (Baraclude) Formulary Evaluation Mechanism of action, Pharmacokinetics, Dosage, Clinical studies, Strengths, Weaknesses, Drug interactions, Adverse reactions, Warnings/precautions, Monitoring, Cost...

Drug Criteria & Outcomes: New FDA Approvals.
December 1, 2005... These drugs were recently approved by the FDA: • Nelarabine (Arranon) by GlaxoSmithKline. The FDA has approved nelarabine (Arranon) to treat adults and children with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic...

CE objectives/questions.
December 1, 2005... CE questions Pharmacists participate in this continuing education program by reading the article, using the provided references for further research, and studying the CE questions. Participants should select what they believe to be the...